Failure of Implantable Cardioverter-defibrillator Pacing Capture in BRASH Syndrome with Severe Hyperkalemia.
- 1Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA.
- 2Department of Cardiology, SSM Health Saint Louis University Hospital, St. Louis, MO, USA.
Abstract
This case report describes a 54-year-old woman with end-stage renal disease and heart failure who presented with BRASH syndrome: a synergistic cycle of bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia. The patient, who was adherent to metoprolol and amiodarone, presented with a profound ventricular escape rhythm of 16 bpm and hemodynamic instability after missing 4 days of hemodialysis. An interesting complication was the failure of her implantable cardioverter-defibrillator (ICD) to achieve pacing capture, a phenomenon likely driven by a potassium level of 7.8 mEq/L causing myocardial inexcitability. Additionally, the recent uptitration of a carotid sinus nerve stimulator for baroreflex activation therapy may have contributed to the bradycardic cycle. Immediate medical management of hyperkalemia with calcium, insulin, and dextrose successfully restored ICD capture, followed by emergent dialysis, which normalized her rhythm. This case emphasizes that BRASH syndrome should be considered in undifferentiated bradycardia, particularly when refractory to atropine, and highlights that correcting the underlying metabolic derangement is essential to restoring cardiac excitability and device function.
Related
- Long-term predictors of outcome in Brugada syndrome patients after implantable cardioverter-defibrillator implant.
- Radiofrequency ablation with a conventional solid tip catheter in contact with an implantable cardioverter-defibrillator coil causing inadvertent ventricular fibrillation.
- Ventricular fibrillation treated by an implantable cardioverter-defibrillator in antimitochondrial M2 antibody-positive myocarditis.
- Transient defibrillation threshold elevation associated with air in the generator pocket after extravascular implantable cardioverter-defibrillator implantation.
- Intraoperative preservation of an extravascular implantable cardioverter-defibrillator lead during coronary artery bypass grafting.
BibTeX
@article{roche2026failure,
title = {{Failure of Implantable Cardioverter-defibrillator Pacing Capture in BRASH Syndrome with Severe Hyperkalemia.}},
author = {Stephen Roche and Michael Kanan and Deana Mikhalkova},
journal = {The Journal of innovations in cardiac rhythm management},
year = {2026},
month = jul,
doi = {10.19102/icrm.2026.17071},
url = {https://europepmc.org/article/MED/42899269},
note = {CC BY},
}
RIS
TY - JOUR
TI - Failure of Implantable Cardioverter-defibrillator Pacing Capture in BRASH Syndrome with Severe Hyperkalemia.
AU - Stephen Roche
AU - Michael Kanan
AU - Deana Mikhalkova
PY - 2026
DA - 2026/07/15
JO - The Journal of innovations in cardiac rhythm management
DO - 10.19102/icrm.2026.17071
UR - https://europepmc.org/article/MED/42899269
AB - This case report describes a 54-year-old woman with end-stage renal disease and heart failure who presented with BRASH syndrome: a synergistic cycle of bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia. The patient, who was adherent to metoprolol and amiodarone, presented with a profound ventricular escape rhythm of 16 bpm and hemodynamic instability after missing 4 days of hemodialysis. An interesting complication was the failure of her implantable cardioverter-defibrillator (ICD) to achieve pacing capture, a phenomenon likely driven by a potassium level of 7.8 mEq/L causing myocardial inexcitability. Additionally, the recent uptitration of a carotid sinus nerve stimulator for baroreflex activation therapy may have contributed to the bradycardic cycle. Immediate medical management of hyperkalemia with calcium, insulin, and dextrose successfully restored ICD capture, followed by emergent dialysis, which normalized her rhythm. This case emphasizes that BRASH syndrome should be considered in undifferentiated bradycardia, particularly when refractory to atropine, and highlights that correcting the underlying metabolic derangement is essential to restoring cardiac excitability and device function.
SN - 2156-3977
SN - 2156-3993
ER -